Fatigue News and Research

RSS

Certain ethnicities diagnosed with colorectal cancer at younger ages

Even though the possibilities of colorectal cancer increases with age, a new study found that certain ethnicities are starting to be diagnosed with the condition at younger ages than ever before.

30 Jan 2016

UI researchers remind US doctors to watch for two diseases that could be passed from mother to child

While world health leaders race to contain the spread of the mosquito-borne Zika virus in the Americas, researchers at the University of Iowa are reminding doctors in the United States to be on the lookout for two other vector-borne and potentially life-threatening diseases that can be passed from mother to child through the placenta.

30 Jan 2016

Eisai's Halaven receives FDA approval for treatment of patients with metastatic liposarcoma

Eisai Inc. announced today that the U.S. Food and Drug Administration approved Halaven (eribulin mesylate) Injection (0.5 mg per mL) for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.

29 Jan 2016

Zepatier receives FDA approval for treatment of chronic HCV genotypes 1 and 4 infections

The U.S. Food and Drug Administration today approved Zepatier (elbasvir and grazoprevir) with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections in adult patients.

29 Jan 2016

Halaven (eribulin mesylate) approved for treatment of liposarcoma

The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be removed by surgery (unresectable) or is advanced (metastatic). This treatment is approved for patients who received prior chemotherapy that contained an anthracycline drug.

28 Jan 2016

FDA expands use of Opdivo + Yervoy Regimen for BRAF V600 mutant and wild-type advanced melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved Opdivo in combination with Yervoy for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma.

27 Jan 2016

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Astellas US LLC, a United States (U.S.) subsidiary of Tokyo-based Astellas Pharma Inc., and Medivation, Inc. today announced that results from the STRIVE trial of enzalutamide compared to bicalutamide in men with castration-resistant prostate cancer (CRPC) were published in the Journal of Clinical Oncology.

27 Jan 2016

Magnesium Flakes named ‘Best Sports’ product

A pioneering mineral bath soak has scooped the ‘Best Sports’ product accolade at the Natural Lifestyle Product Awards 2015.

From BetterYou Ltd 25 Jan 2016

Chronic fatigue syndrome affects almost 2% of 16-year-olds

In what is believed to be the biggest study of chronic fatigue syndrome (CFS) -- also known as myalgic encephalomyelitis (ME) -- in children to date, researchers at the University of Bristol (UK), have found that almost 2 per cent of 16-year-olds have CFS lasting more than six months and nearly 3 per cent have CFS lasting more than three months (the UK definition).

25 Jan 2016

Positive bosutinib response for elderly blast phase CML patient

A case study suggests that the third-generation tyrosine kinase inhibitor bosutinib may be considered as induction therapy for blast phase chronic myeloid leukaemia in older patients.

22 Jan 2016

PD-L1 inhibition well-tolerated, active in metastatic RCC

The programmed death-ligand 1 inhibitor atezolizumab has a favourable toxicity profile and shows anti-tumour activity in previously treated patients with metastatic renal cell carcinoma, according to phase Ia trial findings.

19 Jan 2016

TG4010 vaccine promising in advanced NSCLC

Addition of the TG4010 vaccine to first-line chemotherapy improves outcomes in patients with advanced non-small-cell lung cancer, show the results of a placebo controlled trial.

19 Jan 2016

Dr Now mobile app delivers first ever international medical diagnosis

Dr Now, Europe's fastest-growing mobile health app created by Now Healthcare Group, has delivered its first ever international medical diagnosis, with a UK patient connected to his UK-based GP from the United States via smartphone video call.

19 Jan 2016

Help beat the blues this Monday with a B12 Boost

Boost your mood and energy levels this Blue Monday (18 January) by topping up your vitamin B12, say natural health pioneers BetterYou.

From BetterYou Ltd 14 Jan 2016

Strathspey Crown Holdings announces acquisition of Novus Via assets

Strathspey Crown Holdings LLC announced today the acquisition of the portfolio companies of Novus Via LP, a Nevada-based venture capital investment firm focused on end-stage development and commercialization of advanced electromagnetic and electrochemical technologies spanning healthcare, clean energy and coherent acoustics. The terms of the transaction were not disclosed.

11 Jan 2016

Does cancer affect memory? An interview with Associate Professor Janette Vardy

The study evaluated cognitive function in patients with colorectal cancer. It characterized the incidence and severity of cognitive impairment in people with colorectal cancer (CRC) compared to healthy controls.

7 Jan 2016

New book reveals that self-criticism can be mentally and physically harmful

A new book by Prof. Golan Shahar of Ben-Gurion University of the Negev reveals that self-criticism can be both mentally and physically harmful, leading to mental disorder, chronic fatigue, chronic pain, and even suicide.

4 Jan 2016

New oral breast cancer drug has potential to combat other types of cancer

Palbociclib, a new oral drug whose efficacy in combating breast cancer has been demonstrated alone and in combination with endocrine therapy, also has potential to combat other types of cancer, according to a literature review and additional original research conducted by experts at the Abramson Cancer Center in the University of Pennsylvania published this month in JAMA Oncology.

30 Dec 2015

New AARDA report highlights key issues and trends at State of Autoimmunity National Summit

What are the known environmental factors that trigger autoimmune disease and what are the latest technologies being developed to measure an individual's exposure to such risks?

29 Dec 2015

Selexipag holds promise for treatment of pulmonary hypertension

Living with pulmonary arterial hypertension is challenging, but the chore of treating the rare heart disease may change following promising clinical trial data to be published in the Dec. 24 issue of the New England Journal of Medicine.

24 Dec 2015